Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr((-/-)) mice

Article

关键词: KAPPA-B LIGAND;    APOPTOSIS-INDUCING LIGAND;    RECEPTOR-DEFICIENT MICE;    BONE-FORMATION;    OSTEOCLAST DIFFERENTIATION;    PLASMA OSTEOPROTEGERIN;    ARTERIAL CALCIFICATION;    MONCKEBERGS SCLEROSIS;    HEMODIALYSIS-PATIENTS;    ENDOTHELIAL-CELLS;   

DOI  :  10.1161/CIRCULATIONAHA.107.707380

来源: SCIE

【 摘 要 】

Background-The role of osteoprotegerin in vascular disease is unclear. Recent observational studies show that serum osteoprotegerin levels are associated with the severity and progression of coronary artery disease, atherosclerosis, and vascular calcification in patients. However, genetic and treatment studies in mice suggest that osteoprotegerin may protect against vascular calcification. Methods and Results-To test whether osteoprotegerin induces or prevents vascular disease, we treated atherogenic diet-fed ldlr((-/-)) mice with recombinant osteoprotegerin (Fc-OPG) or vehicle for 5 months. Vehicle-treated mice developed significant, progressive atherosclerosis with increased plasma osteoprotegerin levels, consistent with observational studies, and approximate to 15% of these atherosclerotic lesions developed calcified cartilage-like metaplasia. Treatment with Fc-OPG significantly reduced the calcified lesion area without affecting atherosclerotic lesion size or number, vascular cytokines, or plasma cholesterol levels. Treatment also significantly reduced tissue levels of aortic osteocalcin, a marker of mineralization. Conclusions-These data support a role for osteoprotegerin in the vasculature as an inhibitor of calcification and a marker, rather than a mediator, of atherosclerosis.

【 授权许可】

Free